1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

It Was Shkreli's Show, But Pharma Was On Trial

 
• By Donna Young

The House Oversight and Government Reform Committee hearing on drug prices was the hottest spot in a very damp and cold Washington on Feb. 4 and former Turing Pharmaceutical Inc. CEO Martin Shkreli gave lawmakers and the overflow-crowd in attendance what they were anticipating: Several big smirky smiles, a lot of eye rolling and a refusal to testify – citing his "Act of Production Privilege" under the Fifth Amendment to the US Constitution at the advice of his counsel.

The House Oversight and Government Reform Committee hearing on drug prices was the hottest spot in a very damp and cold Washington on Feb. 4 and former Turing Pharmaceutical Inc. CEO Martin Shkreli gave lawmakers and the overflow-crowd in attendance what they were anticipating: Several big smirky smiles, a lot of eye rolling and a refusal to testify – citing his "Act of Production Privilege" under the Fifth Amendment to the US Constitution at the advice of his counsel.

And lawmakers were irked, with the panel's ranking member, Rep

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

In Brief: DIOSynVax And ACM Biolabs To Develop Bird Flu Vaccine

 
• By Sushmita Panda

The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.

GSK’s Blujepa Brings Innovation To The Antibiotic Space

 
• By Jessica Merrill

The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.